Genetics in Medicine — Progress and Pitfalls
By Editorial,
The Lancet
| 06. 06. 2015
Untitled Document
Last week, the White House decreed that human germline gene editing in biomedical research is discontinued in the USA until ethical and safety concerns are resolved. This technology involves modification of the genome in germ cells, which can then be inherited and passed on to future generations. “The administration believes that altering the human germline for clinical purposes is a line that should not be crossed at this time”, said John P Holdren, Director of the White House Office of Science and Technology Policy.
In recent years, genome engineering technology has developed the ability to edit DNA more precisely than before. The new technology is based on an enzyme complex that binds and splices DNA at precise locations, and can target a dysfunctional gene by first deleting, then repairing or replacing the target sequence with another molecule. One such technique, CRISPR/Cas—short for clustered regularly interspaced short palindromic repeats—has received attention after a study from China used the technique for the first time to edit nonviable human embryos to disable the gene for β-thalassaemia. However, the study...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...